Endologix Reports Positive Clinical Data from the Ovation LUCY

High Acceptance of Advanced Healthcare Equipment Promoting Growth of a-Si X-ray Flat Panel Detectors | Fact.MR’s Medtech Analysis

Big data and analytics will drive patient outcomes in a big way, and the coming years will witness a growing emphasis on healthcare service providers in the business of gathering and processing patient health data.

KA Imaging Makes Distribution Deal with Malaysia Based BeyMed

BeyMed is an emerging medical solutions company with a great potential,” said Amol Karnick, President and CEO of KA Imaging.

BASMA.com Raises a $3M Series a Round to Scale Up Its Health Tech Platform in the MENA

The UK-based, MENA focused, startup BASMA.com closed $3M in its Series A round of funding led by MEVP with the participation of SOSF, IM capital and returning investors iSME, Cedar Mundi Ventures and IFA capital.

 

The LUCY study was led by an advisory board whose members include: Chairperson Jennifer Ash, MD, Christie Clinic Vein and Vascular Center and Assistant Clinical Professor of Surgery, University of Illinois College of Medicine in Champaign; Venita Chandra, MD, Clinical Assistant Professor of Surgery-Vascular Surgery, Stanford School of Medicine; Monica Hunter, MD, Birmingham Heart Clinic at St. Vincent’s Birmingham; Eva Rzucidlo, MD, McLeod Vascular and Associate Professor of Surgery, Geisel School of Medicine, Dartmouth; and Ageliki Vouyouka, MD, Associate Professor of Surgery and Radiology, Mount Sinai Hospital.

Endologix, Inc. (Nasdaq:ELGX), today announced 30-day results from the LUCY (Evaluation of FemaLes who are Underrepresented Candidates for Abdominal Aortic AneurYsm Repair) study. The data showed that at least 28% more women became eligible for minimally-invasive endovascular aneurysm repair (EVAR) when using the Ovation® Abdominal Stent Graft System. The Ovation System is designed to better suit female anatomy than traditional EVAR options and demonstrated lower mortality and complications when compared to previous EVAR studies. The LUCY study is the first to specifically evaluate EVAR outcomes in women, who have historically been underrepresented in EVAR clinical trials.

Recent clinical articles in The Lancet and the Journal of Vascular Surgery indicate that aneurysms grow faster in women than men, leading to a higher rate of rupture and death. Female anatomy may also be more challenging for most commercial EVAR treatments, leading to less eligibility for EVAR and greater mortality, major complications, and readmissions, when compared to men.

Results of the 30-day LUCY data showed that, in women, the ultra-low profile (14F) Ovation device resulted in:

  • At least 28% greater EVAR eligibility for women with AAA
  • 1.3% major adverse events, the lowest rate reported for EVAR, compared to other contemporary, prospective, post-market registries
  • No deaths
  • No proximal endoleaks
  • No limb occlusion
  • Low readmission rate of 3.9%
  • 100% procedural success

Marc Schermerhorn, MD, Associate Professor of Surgery, Beth Israel Deaconess Medical Center, said, “Analysis of historical EVAR clinical data is showing us a large unmet need for AAA treatments for women. Women are less prone to develop the disease, but, when they do, they have significantly worse outcomes than men. New treatment options that better accommodate female anatomy, thereby increasing access and improving outcomes, may go a long way in rectifying the gender disparity in AAA treatment.”

“It is gratifying to see better early outcomes for women in the LUCY study. The Ovation device was able to accommodate the particular challenges of female anatomy, such as small access vessel diameter, short neck length, and higher neck angulation. In addition, mortality, major adverse events, and readmissions were improved for both sexes,” said Venita Chandra, MD, Clinical Assistant Professor of Surgery-Vascular Surgery, Stanford School of Medicine.”  Chandra concluded,  “I look forward to assessing the durability of these results over the longer term.”

The LUCY study is a prospective, consecutively enrolling, non-randomized, multi-center, post-market registry evaluating the Ovation Platform for the endovascular treatment of AAA in women. The study enrolled a total of 225 patients, including 76 females in the treatment group and 149 males in the control group, at 39 sites in the U.S. The primary endpoint of the study was the 30-day Major Adverse Event (“MAE”) rate. Longer-term data from the LUCY study will be shared after the one-year follow-up.

“We are very pleased with the early LUCY study results, which demonstrate the potential Ovation offers to enable more effective treatment of female AAA patients and significantly improved outcomes for all patients,” said John McDermott, Chief Executive Officer of Endologix.  He went on to say, “We look forward to expanding Ovation’s access to more women in those regions where it is available, and to educating both the clinical community and patients about the unique needs of the female patient and the treatment options that are optimized for them.”

 

spot_img

DON'T MISS

Hyperfine Adds Medtech Leader and Visionary Scott Huennekens as Executive Chairman

Mr. Huennekens’ public boards include Chairman of Acutus Medical (IPO August 2020); Chairman of Envista (IPO September 2019); and board member of Nuvasive. He also serves as a board member and past Chairman of the Medical Device Manufacturer’s Association (MDMA).

One Drop Reports Carrie Siragusa, CPA Appointed VP of Commercial Strategy, Biosensor

Formerly Head of Innovation and Diabetes Portfolio at Sanofi, Siragusa will be part of a team bringing a multi-analyte dermal sensor (biosensor) with continuous health sensing capabilities to market with a mission to provide broader access to continuous glucose monitoring.

Barbara Moorhouse Appointed as Medica Non-Executive Director

Barbara has extensive business and management experience in the private, public, and regulated sectors.

Subscribe to Medical Device News Magazine here.

Related Articles